Education
About Us
Working with TipRanks
Follow Us
Vivos Therapeutics (VVOS)
NASDAQ:VVOS
VVOS Analyst Ratings
Moderate Buy
1 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
VVOS Stock 12 Month Forecast
Average Price Target
$5.50
▲(92.98% Upside)
| Highest Price Target$5.50 | Average Price Target$5.50 | Lowest Price Target$5.50 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Alliance Global Partners
Reiterated
04/01/25
Ascendiant
$6.6
Buy
131.58%
Upside
Reiterated
11/19/24
We are raising our FY24 EPS estimates to $(1.79) from $(3.13) on lower costs and higher share count. We are trimming our FY24 revenue estimate to $15.2 million from $16.3 million. We are raising our FY25 estimate to $(1.43), from $(2.47) previously, on revenues of $18.3 million, versus $19.2 million previously. Consensus estimates are $(3.13) and $(2.47) on revenues of $16.3 million and $19.2 million for FY24 and FY25, respectively. FDA approves use of Vivos CARE appliances to treat moderate to severe OSA in children: Vivos announced receipt of FDA 510(k) clearance to treat moderate to severe sleep apnea in children, a first in the industry. The clearance complements approval granted in November 2023 for use of Vivos’ flagship CARE appliances to treat severe OSA in adults. Both are welcome validations of Vivos’ non-surgical approach to curing OSA.
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Alliance Global Partners
Reiterated
04/01/25
Ascendiant
$6.6
Buy
131.58%
Upside
Reiterated
11/19/24
We are raising our FY24 EPS estimates to $(1.79) from $(3.13) on lower costs and higher share count. We are trimming our FY24 revenue estimate to $15.2 million from $16.3 million. We are raising our FY25 estimate to $(1.43), from $(2.47) previously, on revenues of $18.3 million, versus $19.2 million previously. Consensus estimates are $(3.13) and $(2.47) on revenues of $16.3 million and $19.2 million for FY24 and FY25, respectively. FDA approves use of Vivos CARE appliances to treat moderate to severe OSA in children: Vivos announced receipt of FDA 510(k) clearance to treat moderate to severe sleep apnea in children, a first in the industry. The clearance complements approval granted in November 2023 for use of Vivos’ flagship CARE appliances to treat severe OSA in adults. Both are welcome validations of Vivos’ non-surgical approach to curing OSA.
VVOS Analyst Recommendation Trends
Rating
Apr 24
May 24
Aug 24
Nov 24
Apr 25
Strong Buy
2
3
3
4
4
Buy
1
0
0
0
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
3
3
3
4
4
Each month's total comprises the sum of three months' worth of ratings.
VVOS Financial Forecast
VVOS Stock Forecast FAQ
What is VVOS’s average 12-month price target, according to analysts?
Based on analyst ratings, Vivos Therapeutics’s 12-month average price target is $5.50.
What is VVOS’s upside potential, based on the analysts’ average price target?
Vivos Therapeutics has 92.98% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is VVOS a Buy, Sell or Hold?
Vivos Therapeutics has a consensus rating of Moderate Buy which is based on 1 buy ratings, 0 hold ratings and 0 sell ratings.
What is Vivos Therapeutics’s price target?
The average price target for Vivos Therapeutics is $5.50. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $5.50 ,the lowest forecast is $5.50. The average price target represents 92.98% Increase from the current price of $2.85.
The highest analyst price target is $5.50 ,the lowest forecast is $5.50. The average price target represents 92.98% Increase from the current price of $2.85.
What do analysts say about Vivos Therapeutics?
Vivos Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
How can I buy shares of VVOS?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.